Clinical trial NCT01925742: Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood
Official title: PEGASUS: PErsonalized Genomics for Prenatal Aneuploidy Screening USing Maternal Blood
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Trisomy 21
Trisomy 18
Trisomy 13
Keywords: Fetal aneuploidy
Lead sponsor: CHU de Quebec-Universite Laval
Sponsor class: OTHER
Collaborators: name: Laval University
name: Genome Canada
name: Genome Quebec
name: Genome British Columbia
name: Canadian Institutes of Health Research (CIHR)
First posted: 2013-08-20
Enrollment: 3819
Sex: FEMALE
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: Each year, 450,000 Canadian women become pregnant and, as a result of their participation in prenatal screening for Down syndrome, approximately 10,000 of them will have an amniocentesis (i.e. sampling of liquid surrounding the fetus) and of those, 315 will be found to carry a baby with Down syndrome and 70 normal pregnancies will be lost from complications of the procedure. It has been discovered recently that, during pregnancy, there is fetal DNA in maternal blood in sufficient quantities to be analysed and methods have been proposed to detect the presence or not of a fetus with Down syndrome using maternal blood. The introduction of genomic blood testing as proposed in the context of this project could lead to increased detection of Down syndrome, less invasive screening with 9700 amniocentesis avoided each year in Canada, improving the peace of mind of pregnant women, and preventing the accidental loss of 70 normal fetuses, at a lower overall cost than current practice. However, these methods still need to be validated before being appropriately introduced in routine care.

The study hypothesis is that new genomics-based non-invasive methods using fetal-DNA in maternal blood during pregnancy can be more effective than current prenatal screening methods for fetal aneuploidy.

This project will carry out an independent study that will validate the performance and utility of different new genomic technologies for screening in pregnant women using maternal blood. The team of researchers will compare the real-life performance of different non-invasive assays and strategies to screen for fetal aneuploidy, and identify an evidence-based cost-effective approach for implementation of this new technology in the Canadian health care system. The deliverables of this project will enable decision makers, pregnant women and their partner to make informed choices pertaining to prenatal genetic screening and diagnosis, such as screening for Down syndrome, and reduce the risk to pregnancies associated with amniocentesis.

Detailed description: The present study is a real life comparative effectiveness study that will compare the performances and costs of several prenatal screening modalities for fetal aneuploidy (see interventions).

Eligibility criteria: Inclusion Criteria (High risk arm):

* women 19 years or older between 10 weeks and 23 weeks 6 days gestation undergoing amniocentesis or CVS for:
* positive prenatal screen;
* abnormal ultrasound
* previous pregnancy with trisomy
* patient or partner carrier of Robertsonian translocation involving chr 21
* positive NIPT result
* Maternal age 40 or more

Inclusion Criteria (Low risk arm):

* women 19 years and older who are 10 and 13 weeks 6 days gestation based on dating ultrasound (CRL) and are undergoing screening for Down syndrome (first trimester combined, SIPS or IPS)

Exclusion Criteria:

* women with multiple gestations
* women with twin demise (spontaneous or elective) at any gestational age
* women with active or history of malignancy

Primary outcomes:
measure: Number of cases with Fetal trisomy 21, 18 or 13
timeFrame: 6 weeks after the delivery date
Secondary outcomes:
measure: Number of women with assay failure
timeFrame: At end of pregnancy.
Other outcomes:
measure: Overall costs of screening algorithm
timeFrame: 6 weeks after delivery
Locations:
city: Calgary
country: Canada
facility: Foothills Medical Centre
state: Alberta
city: Vancouver
country: Canada
facility: Children's & Women's Health Centre
state: British Columbia
city: Ottawa
country: Canada
facility: The Ottawa Hospital
state: Ontario
city: Montreal
country: Canada
facility: CHU Ste-Justine
state: Quebec
city: Quebec City
country: Canada
facility: CHU de Québec
state: Quebec
Study officials:
affiliation: Universite Laval and CHU de Quebec
name: Francois Rousseau, MD MSc FRCPC
role: PRINCIPAL_INVESTIGATOR
affiliation: University of British Columbia
name: Sylvie Langlois, MD FRCPC
role: PRINCIPAL_INVESTIGATOR
References:
citation: Fibke C, Giroux S, Caron A, Starks E, Parker JDK, Swanson L, Jouan L, Langlois S, Rouleau G, Rousseau F, Karsan A. Effect of preexamination conditions in a centralized-testing model of non-invasive prenatal screening. Clin Chem Lab Med. 2021 Nov 11;60(2):183-190. doi: 10.1515/cclm-2021-0652. Print 2022 Jan 27.
citation: Rousseau F, Langlois S, Johnson JA, Gekas J, Bujold E, Audibert F, Walker M, Giroux S, Caron A, Clement V, Blais J, MacLeod T, Moore R, Gauthier J, Jouan L, Laporte A, Diallo O, Parker J, Swanson L, Zhao Y, Labelle Y, Giguere Y, Forest JC, Little J, Karsan A, Rouleau G. Prospective head-to-head comparison of accuracy of two sequencing platforms for screening for fetal aneuploidy by cell-free DNA: the PEGASUS study. Eur J Hum Genet. 2019 Nov;27(11):1701-1715. doi: 10.1038/s41431-019-0443-0. Epub 2019 Jun 23.